Hesch R D
HNO. 1982 Oct;30(10):365-74.
I propose an analogy between vascular diseases of the inner ear and those of other organs like brain, heart or peripheral vessel diseases in which functional and organic alteration can be objectively demonstrated. Symptomatic disturbances of inner ear circulation are monoform in its clinical appearance and the term of 'otangina' is proposed for the functional result. Three types of vascular distribution are discussed for the different regulatory entities, (I) the proximal cerebral vascular type, (II) the predistal innervated regulatory type and the (III) capillary regulatory type. The formal etiology of inner ear vascular diseases is is developed on the base of organic vascular lesions, i.e. arteriosclerosis, functional alterations, i.e. vasospastic disease, and finally change in the microcirculation by alterations of the rheology of the blood. Hypertension is portrayed as a main example for cardiovascular risk factors with respect to inner ear circulatory damage but diabetes mellitus, cigarette smoking and other metabolic diseases leading to vascular disturbances have to be considered. From these considerations I have developed a basic program for the diagnosis of vascular metabolic risk factors which should be realized before any treatment is advocated. I have critically evaluated the benefit and possible hazardous effects of so called 'vasoactive' and 'cephalotropic' drugs. For most inner ear circulatory disease such therapy is contraindicated. The models of drug treatment of acute deafness and the chronic or persistent inner ear deafness should be evaluated in prospective studies.
我提出内耳血管疾病与其他器官的血管疾病(如脑、心脏或外周血管疾病)之间存在类比关系,在这些疾病中,功能和器质性改变可以得到客观证实。内耳循环的症状性紊乱在临床表现上具有单一性,因此提出“耳绞痛”这一术语来描述其功能结果。针对不同的调节实体,讨论了三种血管分布类型:(I)近端脑血管类型,(II)节前神经支配调节类型,以及(III)毛细血管调节类型。内耳血管疾病的形式病因是基于器质性血管病变(即动脉硬化)、功能性改变(即血管痉挛性疾病),以及最终因血液流变学改变导致的微循环变化而形成的。高血压被描述为内耳循环损伤的心血管危险因素的主要例子,但糖尿病、吸烟和其他导致血管紊乱的代谢性疾病也必须予以考虑。基于这些考虑,我制定了一个诊断血管代谢危险因素的基本方案,该方案应在倡导任何治疗之前实施。我对所谓的“血管活性”和“亲脑性”药物的益处和可能的有害影响进行了批判性评估。对于大多数内耳循环疾病,这种治疗是禁忌的。急性耳聋和慢性或持续性内耳耳聋的药物治疗模式应在前瞻性研究中进行评估。